Investigating the Influence of Everolimus, Recombinant TGF-alpha, and Methotrexate on Cell Cycle Phases in Human Cancer Cell Lines

Abstract

Abstract The disruption of cell cycle phases is one of the characteristics acquired by tumor cells during the process of carcinogenesis. In this study, we investigated the differences in cell cycle phases among human cell lines derived from triple-negative (BT-549), colorectal (RKO-AS45-1), and ovarian (TOV-21G) cancers treated with everolimus, recombinant TGF-alpha, and Methotrexate (MTX). Our data showed that MTX induced the transition from G1 to S phase in TOV-21G, while TGF-alpha decreased the percentage of cells in G1. For the triple-negative breast cancer (TNBC) cell line, TGF-alpha reduced the number of cells in G1. In the case of the RKO-AS45-1 cell line, no treatment affected the dynamics of the cell cycle in these cells, indicating intrinsic resistance to the treatments used.

Keywords

• everolimus
• recombinant tgf-alpha
• methotrexate
• human cancer cell lines
• cell cycle